Shares of Renalytix Plc (LON:RENX – Get Free Report) fell 11.1% during mid-day trading on Friday . The company traded as low as GBX 1.60 and last traded at GBX 1.60. 428,751 shares changed hands during trading, a decline of 53% from the average session volume of 919,401 shares. The stock had previously closed at GBX 1.80.
Renalytix Stock Performance
The business’s 50-day moving average price is GBX 1.94 and its 200-day moving average price is GBX 4.26. The company has a debt-to-equity ratio of -118.57, a quick ratio of 2.42 and a current ratio of 1.21. The stock has a market cap of £6.99 million, a P/E ratio of -0.40 and a beta of 1.97.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Read More
- Five stocks we like better than Renalytix
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
